Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (111-120 of 1,833) with videos related to

Pageof 184
Sort By:
Mabs|January 19, 2010
Target mediated disposition of T84.66, a monoclonal anti-CEA antibody: application in the detection of colorectal cancer xenograftsShweta R Urva, Joseph P Balthasar
Mabs|January 5, 2010
Engineered CH2 domains (nanoantibodies)Dimiter S Dimitrov
Mabs|January 5, 2010
Are mAbs different?: a comment on Cohen and WilsonPeter J Neumann
Mabs|January 15, 2010
Directed evolution of an anti-human red blood cell antibodyAmita Gupta, Vijay K Chaudhary, Rajiv Bhat
Mabs|January 16, 2010
IgG2m4, an engineered antibody isotype with reduced Fc functionZhiqiang An, Gail Forrest, Renee Moore, et al.
Mabs|January 16, 2010
Patenting antibodies in EuropeLouise Holliday
Mabs|January 12, 2010
Trends in capacity utilization for therapeutic monoclonal antibody productionEric S Langer
Mabs|January 12, 2010
Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaRJennifer S Michaelson, Stephen J Demarest, Brian Miller, et al.
Mabs|September 24, 2016
Stability of isolated antibody-antigen complexes as a predictive tool for selecting toxin neutralizing antibodiesPatricia M Legler, Jaimee R Compton, Martha L Hale, et al.
Mabs|September 24, 2016
Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicitySihem Ait-Oudhia, Meric Ayse Ovacik, Donald E Mager
Pageof 184

Showing results (111-120 of 1,833) with videos related to

Sort By:
Pageof 184
Mabs|January 19, 2010
Target mediated disposition of T84.66, a monoclonal anti-CEA antibody: application in the detection of colorectal cancer xenograftsShweta R Urva, Joseph P Balthasar
Mabs|January 5, 2010
Engineered CH2 domains (nanoantibodies)Dimiter S Dimitrov
Mabs|January 5, 2010
Are mAbs different?: a comment on Cohen and WilsonPeter J Neumann
Mabs|January 15, 2010
Directed evolution of an anti-human red blood cell antibodyAmita Gupta, Vijay K Chaudhary, Rajiv Bhat
Mabs|January 16, 2010
IgG2m4, an engineered antibody isotype with reduced Fc functionZhiqiang An, Gail Forrest, Renee Moore, et al.
Mabs|January 16, 2010
Patenting antibodies in EuropeLouise Holliday
Mabs|January 12, 2010
Trends in capacity utilization for therapeutic monoclonal antibody productionEric S Langer
Mabs|January 12, 2010
Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaRJennifer S Michaelson, Stephen J Demarest, Brian Miller, et al.
Mabs|September 24, 2016
Stability of isolated antibody-antigen complexes as a predictive tool for selecting toxin neutralizing antibodiesPatricia M Legler, Jaimee R Compton, Martha L Hale, et al.
Mabs|September 24, 2016
Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicitySihem Ait-Oudhia, Meric Ayse Ovacik, Donald E Mager
Pageof 184